DrakeWM, KendlerDL, BrownJP.Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual foothills meeting on osteoporosis, Calgary, Alberta, Canada, September 9–10, 2000. Clin Ther.2001;23:620–6.
2.
WoodJ, BonjeanK, RuetzS, BellahceneA, DevyL, FoidartJM, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther.2002;302:1055–61.
3.
LinJH, RussellG, GertzB.Pharmacokinetics of alendronate: an overview. Int J Clin Pract.1999;101(suppl):18–26.
4.
MarxRE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg.2003;61:1115–7.
5.
RuggieroSL, MehrotraB, RosenbergTJ, EngroffSL.Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg.2004;62:527–34.
6.
MarxRE, SawatariY, FortinM, BroumandV.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg.2005;63:1567–75.
7.
WooSB, HellsteinJW, KalmarJR.Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med.2006;144:753–61.
8.
FarrugiaMC, SummerlinDJ, KrowiakE, HuntleyT, FreemanS, BorrowdaleR, Osteonecrosis of the mandible or maxilla associated with the use of new generation biphosphonates. Laryngoscope.2006;116:115–20.
